Cited 7 times in
Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김성렬 | - |
dc.contributor.author | 박경희 | - |
dc.contributor.author | 박중원 | - |
dc.contributor.author | 범승훈 | - |
dc.contributor.author | 신상준 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 이재현 | - |
dc.date.accessioned | 2021-09-29T01:51:25Z | - |
dc.date.available | 2021-09-29T01:51:25Z | - |
dc.date.issued | 2021-07 | - |
dc.identifier.issn | * | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/184584 | - |
dc.description.abstract | Background: Cetuximab (chimeric monoclonal antibody to human epidermal growth factor receptor) is used to treat colorectal and head and neck cancers. Due to cross-reactivity with galactose-α-1,3-galactose (alpha-gal), it can induce hypersensitivity even at first administration. We aimed to determine the incidence and clinical manifestation of cetuximab-induced anaphylaxis, and to establish a means of predicting its incidence in patients ahead of treatment. Methods: Nationwide and single-center pharmacovigilance data from 2010 to 2017 were collected from the Korea Institute of Drug Safety-Korea Adverse Event Reporting System and Severance Regional Pharmacovigilance Center. Patients scheduled for cetuximab administration were enrolled prospectively. A skin prick test was carried out and serum IgE specific to cetuximab and cross-reactive allergens were measured. Reactions were monitored after cetuximab infusion. Results: Over 8 years, there were 23 reports of anaphylaxis nationwide. In a single-center study, incidence of cetuximab-induced anaphylaxis was 1.1%. Most anaphylaxis occurred at first injection (93.3%), even under pretreatment with anti-allergic drugs. Four of 64 patients (6.3%) experienced severe anaphylaxis. The median cetuximab-specific IgE titer was 6.9 kUA/L in patients experiencing anaphylaxis and 0 kUA/L in those who did not (P < 0.001). The results of alpha-gal, beef sIgE, and cetuximab skin prick testing were similar to those of cetuximab sIgE. Patients who did not experience hypersensitivity were negative in all 4 allergy tests. Its positive and negative predictive values were 100%. Conclusions: Specific IgE detection of cetuximab or alpha-gal can accurately predict cetuximab-induced anaphylaxis prior to first administration. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier Inc. | - |
dc.relation.isPartOf | WORLD ALLERGY ORGANIZATION JOURNAL | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Kyung Hee Park | - |
dc.contributor.googleauthor | Jongsun Lee | - |
dc.contributor.googleauthor | Seung Hoon Beom | - |
dc.contributor.googleauthor | Sang Joon Shin | - |
dc.contributor.googleauthor | Joong Bae Ahn | - |
dc.contributor.googleauthor | Sung-Ryeol Kim | - |
dc.contributor.googleauthor | Jae-Hyun Lee | - |
dc.contributor.googleauthor | Jung-Won Park | - |
dc.identifier.doi | 10.1016/j.waojou.2021.100553 | - |
dc.contributor.localId | A00566 | - |
dc.contributor.localId | A01427 | - |
dc.contributor.localId | A01681 | - |
dc.contributor.localId | A04581 | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A03086 | - |
dc.relation.journalcode | J03985 | - |
dc.identifier.eissn | 1939-4551 | - |
dc.identifier.pmid | 34257795 | - |
dc.subject.keyword | Anaphylaxis | - |
dc.subject.keyword | Cetuximab | - |
dc.subject.keyword | Specific IgE | - |
dc.contributor.alternativeName | Kim, Sung Ryeol | - |
dc.contributor.affiliatedAuthor | 김성렬 | - |
dc.contributor.affiliatedAuthor | 박경희 | - |
dc.contributor.affiliatedAuthor | 박중원 | - |
dc.contributor.affiliatedAuthor | 범승훈 | - |
dc.contributor.affiliatedAuthor | 신상준 | - |
dc.contributor.affiliatedAuthor | 안중배 | - |
dc.contributor.affiliatedAuthor | 이재현 | - |
dc.citation.volume | 14 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 100553 | - |
dc.identifier.bibliographicCitation | WORLD ALLERGY ORGANIZATION JOURNAL, Vol.14(7) : 100553, 2021-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.